X4 Pharmaceuticals, Inc. (XFOR)

Nasdaq: XFOR · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2010

Grade4.2

◀ Past 1.8● Present 3.4▶ Future 6.3

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Report filed	Mar 17, 2026	Mar 26, 2025	Mar 21, 2024	Mar 21, 2023	Mar 17, 2022	Mar 19, 2021	Mar 12, 2020	Mar 11, 2019	Mar 9, 2018	·
Revenue	35,113	2,557	0	0	0	3,000	0	0^r	·	·
Cost of revenue	5,757	797	0	0	·	·	·	·	·	·
Research and development	72,723	81,643	72,017	61,058	50,647	41,932	30,163	20,346^r	17,066^r	17,831
General and administrative	43,516	61,518	35,505	27,020	24,702	20,942	17,640	8,739^r	5,181^r	6,515
Total operating expenses	·	·	107,522	87,569	85,107	62,874	51,703	29,085^r	22,247^r	24,346
Total costs and expenses	·	38,958	107,522	87,569	·	·	·	·	·	·
Operating income	-86,883	-36,401	-107,522	-87,569	-85,107	-59,874	-51,703	-29,085^r	-22,247^r	-24,346
Interest expense	8,876	8,768	5,777	3,993	3,642	2,688	2,147	720^r	490^r	2,515
Interest and investment income	4,576	5,769	4,582	219	10	273	1,197	236^r	64^r	·
Other income (expense), net	-753	332	554	-4,197	426	905	517	0^r	0^r	104
Total non-operating income (expense)	7,725	-739	6,433	-6,270	-3,572	-2,109	-1,104	-4,200^r	253^r	1,371
Income before income taxes	-79,158	-37,140	-101,089	-93,839	-88,679	-61,983	-52,807	-33,285	-21,994^r	-22,975
Income tax expense	41	310	78	28	17	148	0	0	·	·
Net income including non-controlling interests	·	-37,450	-101,167	-93,867	-88,696	-62,131	-52,807	-33,285	-21,994	·
Net income	-79,199	-37,450	-101,167	-93,867	-88,696	-62,131	-52,807	-33,285^r	-21,994^r	-22,975
Net income to common shareholders	·	-37,450	-101,167	-96,413	-102,639	-62,131	-53,399	-36,307^r	-24,994^r	-23,000
Earnings per share, basic	-1.87	-5.59^r	-17.07^r	-45.60^b	-119.70^b	-92.70^b	·	·	·	·
Earnings per share, diluted	-1.87	-5.59^r	-17.07^r	-45.60^b	-119.70^b	-92.70^b	·	·	·	·
Earnings per share, basic and diluted	·	·	·	·	-119.70^b	-92.70^b	-138.90^b	-2,374.50^rb	-1,637.40^rb	-1,343.70^b
Weighted average shares, basic	42,292,818	6,702,073^r	5,927,082^r	2,117,528^rb	858,293^rb	669,233^b	·	·	·	·
Weighted average shares, diluted	42,292,818	6,702,073^r	5,927,082^r	2,117,528^rb	858,293^rb	669,233^b	·	·	·	·
Weighted average shares, basic and diluted	·	·	·	·	858,300^b	669,233^b	384,333^b	15,300^rb	15,267^rb	17,118^b

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-30 reverse split of Apr 2025.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue

Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense

General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense

Total operating expenses the running costs togetherus-gaap:OperatingExpenses

Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest expense what its borrowing cost

us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense

Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest

Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before tax

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

SI Assistanton XFOR · research, not advice